Abstract
Proteolysis is doubtlessly the most widespread mechanism of biological regulation. By controlling protein synthesis, turnover and activity, it is involved in fundamental physiological processes including apoptosis, cell differentiation, growth and signaling, fertilization, immune response, blood coagulation and digestion. Yet, uncontrolled proteolysis can be harmful for organisms, causing - amongst others - such diseases as cancer, emphysema, inflammation, and neurodegenerative, immunological, and cardiovascular disorders. This paper briefly describes recent advances in the development of methodological design to follow up protease activity. Novel methods of protease sensing are described and evaluated. A variety of fluorescent reporter molecules including nanoparticles, and rare metal chelates are also characterized.
Keywords: Protease, substrate, fluorescence, reporter molecules.
Current Pharmaceutical Design
Title:Future of Protease Activity Assays
Volume: 19 Issue: 6
Author(s): Magdalena Wysocka and Adam Lesner
Affiliation:
Keywords: Protease, substrate, fluorescence, reporter molecules.
Abstract: Proteolysis is doubtlessly the most widespread mechanism of biological regulation. By controlling protein synthesis, turnover and activity, it is involved in fundamental physiological processes including apoptosis, cell differentiation, growth and signaling, fertilization, immune response, blood coagulation and digestion. Yet, uncontrolled proteolysis can be harmful for organisms, causing - amongst others - such diseases as cancer, emphysema, inflammation, and neurodegenerative, immunological, and cardiovascular disorders. This paper briefly describes recent advances in the development of methodological design to follow up protease activity. Novel methods of protease sensing are described and evaluated. A variety of fluorescent reporter molecules including nanoparticles, and rare metal chelates are also characterized.
Export Options
About this article
Cite this article as:
Wysocka Magdalena and Lesner Adam, Future of Protease Activity Assays, Current Pharmaceutical Design 2013; 19 (6) . https://dx.doi.org/10.2174/1381612811319060008
DOI https://dx.doi.org/10.2174/1381612811319060008 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Structure-Function Relationships in the Interaction Between the Urokinase- Type Plasminogen Activator and Its Receptor
Current Pharmaceutical Design Anticancer Immunotherapy in Combination with Proapoptotic Therapy
Current Cancer Drug Targets Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies
Current Cancer Drug Targets Editorial
Recent Patents on Anti-Cancer Drug Discovery Emerging Therapies in Chronic Myeloid Leukemia
Current Cancer Drug Targets Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans
Infectious Disorders - Drug Targets Clinical Development of Microbicides for the Prevention of HIV Infection
Current Pharmaceutical Design Axitinib in the Treatment of Head and Neck Malignancies
Current Clinical Pharmacology Identification and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators
Current Medicinal Chemistry - Anti-Cancer Agents The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology Multidisciplinary Treatment of Early Stage Endometrial Cancer
Anti-Cancer Agents in Medicinal Chemistry Editorial (Hot Topic: Modifying Cardiovascular Risk Factors: New Markers of Cardiovascular Damage)
Current Pharmaceutical Design Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets News in the Indications of Direct Oral Anticoagulants According to the American College of Chest Physicians 2016 Guidelines
Current Drug Metabolism Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview
Current Medicinal Chemistry Effects of Galantamine in Alzheimers Disease: Double-blind Withdrawal Studies Evaluating Sustained Versus Interrupted Treatment
Current Alzheimer Research Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy
Current Gene Therapy Prostate-Apoptosis-Response-Gene-4: Biological Properties and their Potential Therapeutic Exploitation in Hematological Malignancies
Letters in Drug Design & Discovery